Amneal Makes Strategic Investment in Ireland

Minister for Jobs Richard Bruton TD has announced that Amneal Pharmaceuticals has purchased a 200,000-sq ft facility in Cashel, County Tipperary, Ireland.

The former Johnson & Johnson (J&J) plant was sold by owner Solidus Private Equity, a Singapore-based 
investment firm. Amneal worked closely with Foreign Direct Investment agency IDA Ireland. The investment is supported by the Department of Jobs, Enterprise and Innovation through IDA Ireland.

The Cashel site will be dedicated to R&D and production of metered dose and dry powder inhalers (MDIs and DPIs) as well as biosimilars — all high-end specialty medications — with each product occupying approximately 50% of the building. Amneal expects to hire an estimated 250–300 employees at full build-out.

“Our new Ireland facility is critical to Amneal’s long-term global growth, in Europe, the US and throughout the world,” explained Chintu Patel, Amneal Co-CEO and Co-Chairman. “We appreciate the outstanding support from IDA Ireland and others in helping us establish ourselves in County Tipperary and are excited to launch our operations here.”

Martin Shanahan, CEO of IDA Ireland said: “Regional development is a core part of IDA Ireland’s strategy. This announcement is great news for Tipperary and the whole of the South East region. That Amneal has chosen to locate in a facility that had been occupied previously is especially pleasing and is a credit to the IDA executives who are advertising relentlessly ready-to-go sites just like this in boardrooms across the world on a daily basis.”

Besides the availability of the J&J plant, Amneal chose Cashel for the quality of its local workforce, the enthusiastic support of government leaders and a positive business environment. The company in turn brings to Cashel a proven track record of providing steady jobs, empowering employees to do their best work and collaborating with the surrounding community to build a superb operation aligned with Amneal’s core values.

To become a world-class generics player, Amneal is targeting expansion in Europe, Australia, Japan, Southeast Asia and Latin America. Pursuing strategic acquisitions or partnerships in Ireland and other countries that welcome US businesses, as well as diversifying into complex, high-value products, will fuel the company’s smart, sustainable growth for years to come.